Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Meta Expands AI Training With Employee Activity Tracking Tools 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
- Dr. Joseph Stauffer to deliver opening remarks and discuss kappa opioid receptor agonists as a novel approach to acute and chronic pain management
- Dr. Stauffer serves as co-chair and on the event’s Scientific Advisory Board
STAMFORD, Conn., May 17, 2017 -- Cara Therapeutics, Inc. (NASDAQ:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that Dr. Joseph Stauffer, Cara's Chief Medical Officer, has been selected to speak at the 17th Annual Conference on Pain Therapeutics to be held May 22-23, 2017 in London. Dr. Stauffer also serves as an event co-chair and on the conference’s Scientific Advisory Board.
On Tuesday, May 23, Dr. Stauffer will deliver opening remarks and the opening address, during which he will discuss kappa opioid receptor agonism as a new approach to managing acute and chronic pain. This discussion will highlight positive clinical trial results and human abuse liability data for CR845, the Company's first-in-class peripherally selective kappa opioid agonist. To date, results support the view that CR845 is unlikely to be recreationally abused or lead to physical dependence.
For more information on the 17th Annual Conference on Pain Therapeutics, visit https://www.smi-online.co.uk/pharmaceuticals/uk/pain-therapeutics.
About CR845
CR845 is a peripherally acting kappa opioid receptor agonist currently in development for the treatment of acute and chronic pain and pruritus. In multiple randomized, double-blind, placebo-controlled Phase 2 trials in patients undergoing laparoscopic hysterectomy or bunionectomy procedures, I.V. CR845 treatment resulted in statistically significant reductions in pain intensity and opioid-related side effects. In more than 1200 subjects dosed to date, CR845 was observed to be well-tolerated, without incurring the dysphoric and psychotomimetic side effects that have been reported with centrally acting (CNS-active) kappa opioid receptor agonists, and lacking the respiratory depression and abuse liability of mu opioid receptor agonists. Top-line data from a Phase 2b trial of Oral CR845 in chronic pain associated with osteoarthritis are expected in the second quarter of 2017.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates, led by CR845, that target the body's peripheral nervous system and have demonstrated, in Phase 2 trials, preliminary efficacy in patients with moderate-to-severe pain and pruritus without inducing many of the undesirable side effects typically associated with currently available pain therapeutics.
MEDIA CONTACT: Annie Starr 6 Degrees 973-415-8838 [email protected] INVESTOR CONTACT: Michael Schaffzin Stern Investor Relations, Inc. 212-362-1200 [email protected]
